Roche Gets Second European Approval for Alzheimer’s Test

Why It Matters

The pTau217 assay offers a more definitive, accessible diagnostic tool, potentially accelerating treatment initiation and addressing the large proportion of undiagnosed dementia patients in Europe.

Key Takeaways

• Roche's pTau217 test validates both confirmation and exclusion of Alzheimer’s
• Second CE‑marked blood assay follows earlier pTau181 approval
• Breakthrough device status from FDA accelerates U.S. market entry
• Estimated 75% of dementia patients remain undiagnosed in Europe
• Test slated for European launch in July, targeting primary care

Pulse Analysis

Blood‑based biomarkers are reshaping the diagnostic landscape for Alzheimer’s disease, offering a less invasive and more scalable alternative to cerebrospinal fluid analysis or PET imaging. The Roche‑Lilly collaboration has produced a second Elecsys assay, the pTau217 test, which received a CE mark for sale across the European Economic Area. The regulatory clearance follows the earlier approval of the pTau181 assay and reflects growing confidence among health authorities that plasma markers can reliably reflect cerebral amyloid and tau pathology. This development aligns with broader industry efforts to democratize early detection.

The pTau217 assay distinguishes itself by detecting both the presence and absence of Alzheimer’s‑related tau aggregates, enabling clinicians to confirm a diagnosis or rule it out with a single blood draw. Validated for use in primary‑care settings as well as specialist neurology clinics, the test complements existing imaging tools and could shorten the time from symptom onset to therapeutic intervention. Its breakthrough‑device designation from the U.S. Food and Drug Administration further underscores its clinical promise, positioning the assay as a bridge between early detection and the rapidly expanding portfolio of disease‑modifying antibodies.

From a market perspective, the CE‑marked launch scheduled for July positions Roche to capture a growing demand for accessible Alzheimer’s diagnostics across Europe, where roughly three‑quarters of dementia patients remain undiagnosed. Wider testing could accelerate uptake of recently approved treatments such as Biogen’s Leqembi and Eisai’s Leqembi, as well as Lilly’s Kisunla, by ensuring patients are identified earlier in the disease course. Moreover, the partnership demonstrates how pharma‑diagnostic collaborations can generate integrated solutions, potentially prompting competitors to pursue similar blood‑based platforms to stay competitive.